Citation Tools

Download PDFPDF

FRI0489 Certolizumab pegol is associated with long-term improvements in patient-reported outcomes in psoriatic arthritis: 4-year outcomes from the rapid-psa study
Free

Download to a citation manager

Cite this article as:
Gladman D, Fleischmann R, Harris K, et al
FRI0489 Certolizumab pegol is associated with long-term improvements in patient-reported outcomes in psoriatic arthritis: 4-year outcomes from the rapid-psa study